scholarly journals Functional profiles of Müllerian inhibiting substance/anti-Müllerian hormone (MIS/AMH) in primarily cultured endometrial cancer cells

2021 ◽  
Vol 12 (20) ◽  
pp. 6289-6300
Author(s):  
Sang Il Kim ◽  
Joo Hee Yoon ◽  
Soo Young Hur
Keyword(s):  
Endometrial Cancer ◽  
Cancer Cells ◽  
Müllerian Inhibiting Substance ◽  
Functional Profiles ◽  
Mullerian Inhibiting Substance

scholarly journals Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance

2004 ◽  
Vol 102 (1) ◽  
pp. 111-116 ◽  
Author(s):  
E. J. Renaud ◽  
D. T. MacLaughlin ◽  
E. Oliva ◽  
B. R. Rueda ◽  
P. K. Donahoe
Keyword(s):  
Endometrial Cancer ◽  
Müllerian Inhibiting Substance ◽  
Mullerian Inhibiting Substance

scholarly journals Mullerian Inhibiting Substance Promotes Interferon γ-induced Gene Expression and Apoptosis in Breast Cancer Cells

2003 ◽  
Vol 278 (51) ◽  
pp. 51703-51712 ◽  
Author(s):  
Yasunori Hoshiya ◽  
Vandana Gupta ◽  
Hirofumi Kawakubo ◽  
Elena Brachtel ◽  
Jennifer L. Carey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Interferon Γ ◽  
Müllerian Inhibiting Substance ◽  
Mullerian Inhibiting Substance

Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells

2003 ◽  
Vol 211 (1-2) ◽  
pp. 43-49 ◽  
Author(s):  
Yasunori Hoshiya ◽  
Vandana Gupta ◽  
Dorry L. Segev ◽  
Makiko Hoshiya ◽  
Jennifer L. Carey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Müllerian Inhibiting Substance ◽  
Breast And Prostate Cancer ◽  
Mullerian Inhibiting Substance

Gubernacular development in Müllerian inhibiting substance receptor-deficient mice

2002 ◽  
Vol 89 (1) ◽  
pp. 113-118 ◽  
Author(s):  
J.E. Bartlett ◽  
S.M.Y. Lee ◽  
Y. Mishina ◽  
R.R. Behringer ◽  
N. Yang ◽  
...  
Keyword(s):  
Müllerian Inhibiting Substance ◽  
Deficient Mice ◽  
Mullerian Inhibiting Substance

Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance

2018 ◽  
Vol 18 (7) ◽  
pp. 1054-1063 ◽  
Author(s):  
Ning Ding ◽  
Hong Zhang ◽  
Shan Su ◽  
Yumei Ding ◽  
Xiaohui Yu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Endometrial Cancer ◽  
Cancer Cells ◽  
Chemotherapeutic Agent ◽  
Annexin V ◽  
Chemotherapeutic Agents ◽  
Endometrial Cancer Cell ◽  
Animal Survival ◽  
Apoptosis Level

Background: Endometrial cancer is a common cause of death in gynecological malignancies. Cisplatin is a clinically chemotherapeutic agent. However, drug-resistance is the primary cause of treatment failure. Objective: Emodin is commonly used clinically to increase the sensitivity of chemotherapeutic agents, yet whether Emodin promotes the role of Cisplatin in the treatment of endometrial cancer has not been studied. Method: CCK-8 kit was utilized to determine the growth of two endometrial cancer cell lines, Ishikawa and HEC-IB. The apoptosis level of Ishikawa and HEC-IB cells was detected by Annexin V / propidium iodide double-staining assay. ROS level was detected by DCFH-DA and NADPH oxidase expression. Expressions of drug-resistant genes were examined by real-time PCR and Western blotting. Results: Emodin combined with Cisplatin reduced cell growth and increased the apoptosis of endometrial cancer cells. Co-treatment of Emodin and Cisplatin increased chemosensitivity by inhibiting the expression of drugresistant genes through reducing the ROS levels in endometrial cancer cells. In an endometrial cancer xenograft murine model, the tumor size was reduced and animal survival time was increased by co-treatment of Emodin and Cisplatin. Conclusion: This study demonstrates that Emodin enhances the chemosensitivity of Cisplatin on endometrial cancer by inhibiting ROS-mediated expression of drug-resistance genes.

Sign in / Sign up

Export Citation Format

Share Document